<DOC>
	<DOCNO>NCT00924820</DOCNO>
	<brief_summary>The goal clinical research study learn Avastin ( bevacizumab ) may affect cancer spread meninges brain spinal cord . The safety drug also study . Objectives : 1 . Primary : 1 . Determine preliminary response data intravenous bevacizumab patient NM . As measured clearance malignant cell Cerebrospinal fluid ( CSF ) 2 , 4 , 6 , 12 , 18 , 24 week , every 8 week 54 week , b . Time neurological progression ( TTNP ) 2 . Secondary : 1 . Evaluate safety intravenous bevacizumab patient NM 2 . Further describe efficacy intervention measure 1. improvement MR image evidence disease 2. overall survival 3. maintenance quality life 3 . Determine effect systemically administer bevacizumab CSF , serum , urine Vascular endothelial growth factor ( VEGF ) level level 4 . Correlate change CSF VEGF response measurement . 5 . Correlate primary tumor tissue VEGF expression CSF VEGF level 6 . Correlate urine VEGF level serum CSF VEGF level 7 . Evaluate serum CSF VEGF index</brief_summary>
	<brief_title>A Pilot Study Bevacizumab Neoplastic Meningitis</brief_title>
	<detailed_description>The Study Drug : Bevacizumab design prevent slow growth cancer cell block growth blood vessel . Study Drug Administration : If find eligible take part study , every 2 week , receive bevacizumab vein 1 hour . Study Visits : At Weeks 2 4 : - Samples CSF spinal cord collect check presence cancer cell . - Blood ( 3 tablespoon ) draw routine test check blood 's ability clot normally . - If already Ommaya reservoir tap place , sample CSF brain collect look presence cancer cell . - You ask drug may take experienced side effect . - You neurological exam . At Weeks 6 , 12 , 18 , 24 , every 8 week : - Samples CSF spinal cord collect check presence cancer cell . - Blood ( 3 tablespoon ) draw routine test check blood 's ability clot normally . - If already Ommaya reservoir tap place , sample CSF brain collect look presence cancer cell . - You physical exam ( Weeks . - Your performance status record . - You ask drug may take experienced side effect . - You neurological exam . - You complete questionnaire quality life . - You MRI scan check status disease . - Urine collect test kidney function routine test . If indicated urine collect 24 hour period . Every 2 week , blood pressure measure . Length Study : You study 54 week ( 1 year ) . You take study early disease get bad experience intolerable side effect . End-of-Study Visit : If go study early , follow test procedure perform : - You physical exam . - Your performance status record . - You neurological exam . - Samples CSF spinal cord collect look presence cancer cell . - Blood ( 3 tablespoon ) draw routine test check blood 's ability clot normally . You complete questionnaire quality life . - If already Ommaya reservoir tap place , sample CSF brain collect look presence cancer cell . Follow-up Visits : If go study early , within 4 week last dose study drug , every 4 week 3 month , every 3 month , follow-up visit . The following test procedure perform : - You physical exam . - Your performance status record . - You neurological exam . - Samples CSF spinal collect look presence cancer cell . - Blood ( 3 tablespoon ) draw routine test check blood 's ability clot normally . You MRI scan check status disease . -If already Ommaya reservoir tap place , sample CSF brain collect look presence cancer cell . This investigational study . Bevacizumab FDA approve commercially available treatment colon , breast , lung cancer . Its use treatment cancer spread meninges brain spinal cord investigational . Up 25 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . History breast cancer , lung cancer melanoma 2 . Diagnosis NM proven either : 1. positive CSF cytology , 2. magnetic resonance neuroimaging , 3. 3 . Age &gt; /=18 year . 4 . Routine laboratory study adequate bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , AST &lt; 2.5 x ULN , creatinine &lt; 1.0 x ULN , granulocytes &gt; 1500 , platelets &gt; 75,000 ; Hb &gt; /= 9.0 . 5 . Patient able sign inform consent willing participate study primary objective 6 . At least 1 week last intrathecal chemotherapy ( &gt; 2 week liposomal cytarabine ) . Patients allow receive prior chemotherapy tumor . No limit prior chemotherapy make . Patients treat tyrosine kinase inhibitor permit . Prior antiVEGF target therapy permit , unless patient antiVEGF therapy 6 month develop NM antiVEGF therapy 7 . Karnofsky performance status ( KPS ) &gt; /= 50 % 8 . Pretreatment CSF Indium 111 CSF flow study without evidence obstruction . 9 . Patients fulldose anticoagulant ( e.g. , warfarin ) PT international normalize ratio ( INR ) &gt; 1.5 eligible provide : 1 . Patients receive anticoagulation ( warfarin low molecular weight heparin ( LMWH ) ) patient warfarin 45 day prior LP place LMWH interim , 'treatment dose ' LMWH safely hold 24 hour LP . 10 . ( 9. continue ) INR must &lt; 1.2 prior LP circumstance . If patient receive thromboprophylaxis dose LMWH , patient enrol , thromboprophylaxis LMWH must able safely hold 12 hour prior LP . 2 . The patient active bleed pathological condition carry high risk bleed 3 . There evidence serious nonhealing wound , ulcer bone fracture 11 . Ventricular reservoir NOT mandatory 1 . Evidence active CNS hemorrhage brain tumor lesion 2 . Besides NM , know CNS disease , except treat brain metastasis ( Patients must least 1 month brain irradiation evidence progression hemorrhage time , ascertain clinical examination brain imaging ( MRI CT ) screen period ) . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy , radiosurgery combination deem appropriate treating physician . 3 . ( 2. continue ) With respect irradiation purpose ( NM bone metastasis , etc ) patient need 1 week completion irradiation . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . 4 . Patients clinically significant cardiovascular disease exclude 1 ) Inadequately control HTN ( SBP &gt; 140 mmHg and/or diastolic blood pressure ( DBP ) &gt; 90 mmHg despite antihypertensive medication ) . 2 ) Prior history hypertensive crisis hypertensive encephalopathy . 3 ) New York Heart Association ( NYHA ) Grade II great congestive heart failure . 5 . ( 4 . Continued ) 4 ) History myocardial infarction unstable angina within 6 month prior Day 1 . 5 ) History stroke transient ischemic attack within 6 month prior Day 1 . 6 ) Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 . 7 ) Clinically significant peripheral vascular disease . 8 ) Serious inadequately control cardiac arrhythmia 6 . History hemoptysis ( &gt; /= 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 7 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) 8 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study 9 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 . Ventricular reservoir must place 28 day prior Day 1 . 10 . History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 11 . Serious , nonhealing wound , active ulcer , untreated bone fracture 12 . Proteinuria demonstrate UPC ratio &gt; /=1.0 screen urine dipstick &gt; /= 2+ . ( Patients discover &gt; /= 2+ proteinuria urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; /= 1g protein 24 hour eligible ) . 13 . Known hypersensitivity component bevacizumab 14 . Intrathoracic extrathoracic lung carcinoma squamous cell histology . Mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone acceptable . 15 . ( 14. continue ) Patients extrathoraciconly squamous cell NSCLC eligible . Patients peripheral lung lesion ( non squamous NSCLC histology , except small cell histology ) also eligible ( peripheral lesion define lesion epicenter tumor &lt; /= 2 cm costal diaphragmatic pleura threedimensional orientation base lobe lung &gt; /= 2 cm trachea , main , lobar bronchus ) . 16 . Pregnant ( positive pregnancy test ) nursing woman . Angiogenesis critical fetal development inhibition angiogenesis follow administration AVASTIN likely result adverse effect pregnancy . There adequate wellcontrolled study pregnant woman . Both fertile men woman must agree use adequate contraceptive measure study therapy least 2 month completion bevacizumab therapy . 17 . General Medical Exclusions 1 ) Inability comply study and/or followup procedure 2 ) Life expectancy le 6 week 3 ) Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentech support study 4 ) Active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Neoplastic Meningitis</keyword>
	<keyword>NM</keyword>
	<keyword>Advanced Cancers</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Disorders</keyword>
	<keyword>CNS</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Spinal Cord</keyword>
	<keyword>meninges</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>CSF</keyword>
</DOC>